XFOR Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . X4 Pharmaceuticals
XFOR Stock  USD 0.51  0.01  2.00%   
X4 Pharmaceuticals financial statements provide useful quarterly and yearly information to potential X4 Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on X4 Pharmaceuticals financial statements helps investors assess X4 Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting X4 Pharmaceuticals' valuation are summarized below:
Gross Profit
628 K
Market Capitalization
86.7 M
Enterprise Value Revenue
26.6686
Revenue
1.1 M
Earnings Share
(0.08)
There are over one hundred nineteen available fundamental measures for X4 Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm X4 Pharmaceuticals' latest fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 02/16/2025, Enterprise Value is likely to grow to about 130.6 M, while Market Cap is likely to drop slightly above 72.8 M.
Check X4 Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among X4 Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 4 M, Depreciation And Amortization of 457.8 K or Interest Expense of 7 M, as well as many indicators such as Price To Sales Ratio of 40.66, Dividend Yield of 0.0 or PTB Ratio of 2.76. XFOR financial statements analysis is a perfect complement when working with X4 Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of X4 Pharmaceuticals Correlation against competitors.
To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.

X4 Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets102.4 M169.3 M72.3 M
Slightly volatile
Short and Long Term Debt Total70.4 M67 M26 M
Slightly volatile
Other Current Liabilities15.5 M14.7 M6.5 M
Slightly volatile
Total Current Liabilities13.7 M26.3 M11.6 M
Slightly volatile
Property Plant And Equipment Net4.7 M7.4 M3.4 M
Slightly volatile
Current Deferred Revenue1.2 M847.5 K760.4 K
Slightly volatile
Accounts Payable10.8 M10.3 M3.4 M
Slightly volatile
Cash76.4 M114.1 M53.1 M
Slightly volatile
Non Current Assets Total19.2 M29 M13.2 M
Slightly volatile
Non Currrent Assets Other1.6 M1.7 M1.1 M
Slightly volatile
Cash And Short Term Investments78.2 M131.3 M55.2 M
Slightly volatile
Net Receivables480.5 K505.8 K1.3 M
Slightly volatile
Common Stock Total Equity147.3 K140.3 K45.2 K
Slightly volatile
Common Stock Shares Outstanding214.7 M204.5 M45.3 M
Slightly volatile
Liabilities And Stockholders Equity102.4 M169.3 M72.3 M
Slightly volatile
Non Current Liabilities Total88.5 M84.3 M43.9 M
Slightly volatile
Other Current Assets8.8 M8.4 M2.8 M
Slightly volatile
Other Stockholder Equity638.7 M608.3 M198.2 M
Slightly volatile
Total Liabilities55.9 M110.6 M52.7 M
Slightly volatile
Property Plant And Equipment Gross4.9 M9.2 M3.6 M
Slightly volatile
Total Current Assets83.3 M140.4 M59.2 M
Slightly volatile
Short Term Debt1.9 M989.1 K2.3 M
Slightly volatile
Common Stock201.7 K192.1 K48.7 K
Slightly volatile
Other Liabilities28.1 M26.8 M6.9 M
Slightly volatile
Long Term Debt65.9 M62.8 M24.4 M
Slightly volatile
Short and Long Term Debt1.8 M1.2 M3 M
Slightly volatile
Non Current Liabilities Other748 K496.8 K450.4 K
Slightly volatile
Property Plant Equipment1.2 M1.3 M1.7 M
Slightly volatile
Long Term Debt Total13.9 M23.1 M14 M
Slightly volatile
Capital Surpluse283.1 M518.4 M252.8 M
Slightly volatile
Net Invested Capital104.9 M121.5 M86.9 M
Slightly volatile
Net Working Capital89.4 M114.1 M78.4 M
Slightly volatile
Capital Stock201.7 K192.1 K54.9 K
Slightly volatile
Good Will17 M15.6 M23.9 M
Slightly volatile
Capital Lease Obligations4.9 M4.3 M3.6 M
Slightly volatile
Deferred Long Term Liabilities18.5 M20.8 M22.7 M
Slightly volatile

X4 Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income4 M3.8 M1.1 M
Slightly volatile
Depreciation And Amortization457.8 K481.9 K1 M
Pretty Stable
Interest Expense7 M6.6 M2.5 M
Slightly volatile
Selling General Administrative19.2 M37 M14 M
Slightly volatile
Other Operating Expenses129.8 M123.7 M50.7 M
Slightly volatile
Research Development42 M80.5 M33.1 M
Slightly volatile
Total Operating Expenses129.8 M123.7 M50.7 M
Slightly volatile
Income Tax Expense66.7 K70.2 K935.3 K
Very volatile
Reconciled Depreciation361 K553.1 K286 K
Slightly volatile
Tax Provision50.4 K53.1 K114.7 K
Slightly volatile

X4 Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation10.5 M10 M3.5 M
Slightly volatile
Begin Period Cash Flow148.6 M141.5 M52.4 M
Slightly volatile
Depreciation355.5 K481.9 K355.7 K
Pretty Stable
Capital Expenditures65.5 K69 K226.1 K
Very volatile
End Period Cash Flow77.4 M115.3 M53.7 M
Slightly volatile
Dividends Paid10.2610.827 M
Slightly volatile
Change To Inventory488 K549 K598.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio40.6638.7319.4361
Slightly volatile
Days Sales Outstanding225128225
Slightly volatile
Stock Based Compensation To Revenue1.371.631.6561
Pretty Stable
Capex To Depreciation0.120.130.6693
Very volatile
Inventory Turnover0.320.490.3963
Slightly volatile
Days Of Inventory On Hand1.2 K7641.1 K
Slightly volatile
Payables Turnover0.360.260.5283
Slightly volatile
Sales General And Administrative To Revenue4.96.285.8383
Slightly volatile
Research And Ddevelopement To Revenue9.1312.5810.7036
Slightly volatile
Capex To Revenue0.430.410.1998
Slightly volatile
Cash Per Share0.70.7422.4675
Very volatile
Days Payables Outstanding1.8 K1.9 K1.2 K
Slightly volatile
Income Quality0.710.860.8517
Very volatile
Intangibles To Total Assets0.170.140.1622
Slightly volatile
Current Ratio5.054.814.5575
Slightly volatile
Receivables Turnover1.82.942.0072
Slightly volatile
Graham Number2.12.21115
Slightly volatile
Capex Per Share4.0E-44.0E-40.0927
Slightly volatile
Revenue Per Share0.160.174.3565
Slightly volatile
Interest Debt Per Share0.390.418.6003
Slightly volatile
Debt To Assets0.560.460.5861
Slightly volatile
Operating Cycle122128774
Slightly volatile
Days Of Payables Outstanding1.8 K1.9 K1.2 K
Slightly volatile
Ebt Per Ebit0.780.850.9318
Pretty Stable
Quick Ratio5.034.814.5469
Slightly volatile
Net Income Per E B T1.121.151.062
Very volatile
Cash Ratio4.673.914.1356
Slightly volatile
Days Of Inventory Outstanding1.2 K7641.1 K
Slightly volatile
Days Of Sales Outstanding225128225
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0248
Slightly volatile
Fixed Asset Turnover0.360.387.0561
Slightly volatile
Debt Ratio0.560.460.5861
Slightly volatile
Price Sales Ratio40.6638.7319.4361
Slightly volatile
Asset Turnover0.02670.02810.0657
Slightly volatile
Gross Profit Margin0.780.870.9524
Slightly volatile

X4 Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap72.8 M134.2 M101.5 M
Slightly volatile

XFOR Fundamental Market Drivers

Cash And Short Term Investments114.2 M

XFOR Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About X4 Pharmaceuticals Financial Statements

X4 Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although X4 Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in X4 Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on X4 Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue847.5 K1.2 M
Cost Of Revenue2.3 M2.4 M
Stock Based Compensation To Revenue 1.63  1.37 
Sales General And Administrative To Revenue 6.28  4.90 
Research And Ddevelopement To Revenue 12.58  9.13 
Capex To Revenue 0.41  0.43 
Revenue Per Share 0.17  0.16 
Ebit Per Revenue(22.95)(24.10)

Pair Trading with X4 Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against XFOR Stock

  0.57AMCCF Amcor plcPairCorr
  0.54JNJ Johnson JohnsonPairCorr
  0.51INVA InnovivaPairCorr
  0.51APVO Aptevo TherapeuticsPairCorr
  0.37AMGN Amgen IncPairCorr
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for XFOR Stock Analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY